FDA-APPROVED

Semaglutide

The drug behind Ozempic, Wegovy, and Rybelsus. The most-studied GLP-1 medication, and the one that pulled the whole class into the mainstream conversation.

The 30-second read

Semaglutide is the active ingredient in Ozempic, Wegovy, and Rybelsus, a GLP-1 receptor agonist that helps regulate blood sugar and reduces appetite. It's the drug that turned "GLP-1" into a household phrase. FDA-approved across multiple formulations: weekly injections for type 2 diabetes (Ozempic) and weight management (Wegovy), and a daily oral tablet (Rybelsus). In trials, the highest-dose injectable produced average weight loss around 15 to 17 percent over a year-plus. Solid efficacy, a real cardiovascular benefit signal, and the same trade-offs as the rest of the class. GI side effects, prescription-only access, and a regain pattern when people stop.

Why this peptide is on people's radar

Semaglutide is the drug that turned weight-loss medication into a mainstream news story. Novo Nordisk launched Ozempic for type 2 diabetes in 2017, but it was the off-label use for weight loss, and the eventual FDA approval of Wegovy in 2021, that put it everywhere. By 2023, the conversation had moved well beyond medical journals: Oprah did a network special, tech founders started talking about it on podcasts, and "the Ozempic effect" became shorthand for the entire wave of GLP-1 medications.

The clinical case is what kept the conversation serious. STEP-1, the foundational weight-management trial, showed about 14.9% mean weight loss at the 2.4 mg dose over 68 weeks. The SELECT cardiovascular outcomes trial reported a 20% reduction in major adverse cardiovascular events in adults with overweight or obesity and pre-existing cardiovascular disease, the first time a weight-loss medication had demonstrated that kind of outcome benefit.

The reason interest in semaglutide hasn't faded even as tirzepatide has produced larger weight-loss numbers: it's the most-studied drug in the class, with the longest real-world track record, broader insurance coverage, and now multiple formulations including a daily oral tablet for both diabetes and weight management.

What people are usually trying to do with it

Most people exploring semaglutide are working on one of these:

  • Lose meaningful weight that hasn't responded to diet and exercise alone
  • Manage type 2 diabetes with a drug that also tends to support weight loss
  • Quiet down "food noise", the constant background pull toward eating
  • Lower long-term cardiovascular risk that comes with obesity or T2D
  • Find an oral option (Rybelsus or oral Wegovy) instead of weekly injections

What the science actually shows

Semaglutide has the longest and broadest evidence base of any GLP-1 drug. Plain-English summary of what's been demonstrated:

Weight loss in adults with obesity

The STEP-1 trial reported about 14.9% mean weight loss at 2.4 mg weekly over 68 weeks. STEP-2 (in adults with both T2D and obesity) reported about 9.6%. Newer high-dose Wegovy (7.2 mg) reached around 20.7% in STEP UP.12

Type 2 diabetes outcomes

The SUSTAIN trial program (10 randomized controlled trials) demonstrated significant A1C reductions and cardiovascular benefit signals across diverse patient populations.3

Cardiovascular outcomes

The SELECT trial reported a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with overweight or obesity and established cardiovascular disease over an average follow-up of about 40 months.4

Oral semaglutide

Rybelsus (3, 7, 14 mg daily) showed efficacy comparable to lower-dose injectables for type 2 diabetes. Oral Wegovy (25 mg daily) reached about 16.6% mean weight loss in OASIS-4 over 64 weeks.5

What happens when people stop

The STEP-1 extension showed that participants who stopped semaglutide regained two-thirds of the weight they had lost over the following year. People who continued maintained most of their loss.6

The honest read

What's solid:

One of the best-evidenced metabolic medications ever brought to market. Multiple Phase 3 programs, a positive cardiovascular outcomes trial, and approvals across both diabetes and weight management indications. For people who meet prescribing criteria, the clinical case is well-established.

What's still being worked out:

The best long-term strategy for sustained weight loss after stopping. Comparative effectiveness against tirzepatide (where head-to-head data so far favors tirzepatide). Long-term outcomes across different populations. The right place for the lower-dose oral formulations versus injections.

What's hyped beyond the evidence:

The framing as a one-time fix. The withdrawal data is clear, people who stop tend to regain a meaningful share of the weight. Also: claims about benefits beyond glycemic control, weight, and cardiovascular outcomes (addiction, mood, longevity) that are supported by early-stage research at best, not by the rigorous trials behind the approved indications.

Things to know if you're looking into it

  • How it's used: a once-weekly subcutaneous injection (Ozempic, Wegovy) or a daily oral tablet (Rybelsus, oral Wegovy). Pre-filled pens for the injectables, regular tablets for the oral versions.
  • Brand names: Ozempic (T2D, weekly injection, 2017), Rybelsus (T2D, daily oral, 2019), Wegovy (weight management, weekly injection, 2021), Wegovy HD (weight management, higher-dose weekly, 2025), Oral Wegovy (weight management, daily oral, late 2025/early 2026).
  • Prescription only: all semaglutide formulations are prescription drugs. Compounded "semaglutide" is not the same as the FDA-approved product, and the FDA-approved compounding pathway has narrowed considerably.
  • Common side effects: nausea, diarrhea, constipation, decreased appetite, abdominal pain. Most are dose-dependent and improve with continued dosing. Slow titration is the standard mitigation.
  • Oral versions need empty-stomach timing: Rybelsus and Oral Wegovy must be taken on an empty stomach with a small sip of water, at least 30 minutes before food, beverages, or other oral medications. Absorption is sensitive to stomach contents.
  • Healthcare provider involvement: not optional. Prescribers screen for contraindications (history of medullary thyroid carcinoma, MEN2) and supervise dose escalation.
  • Specific dosing schedule, mechanism, half-life, and full trial detail: all in the "Want to go deeper?" section below.

What people often ask

What's the difference between Ozempic, Wegovy, and Rybelsus?

Same active ingredient (semaglutide), different formulations and labels. Ozempic is a weekly injection approved for type 2 diabetes. Wegovy is a weekly injection at higher maintenance doses approved for weight management. Rybelsus is a daily oral tablet approved for type 2 diabetes. Insurance treats them as different drugs.

How much weight do people actually lose?

Average loss in STEP-1 was about 14.9% over 68 weeks at the 2.4 mg dose. STEP UP at the 7.2 mg dose reported about 20.7%. Individual results vary widely.

Is it better than tirzepatide?

In SURMOUNT-5, the head-to-head trial, tirzepatide produced more weight loss on average (20.2% vs 13.7% at 72 weeks). Semaglutide has a longer real-world track record, more formulation options, and broader insurance coverage. Choosing between them is usually a clinical conversation about what matters most for the individual.

Do you have to stay on it forever?

Practical answer: the drug works while you're taking it. The STEP-1 extension showed people regained about two-thirds of their weight loss within a year of stopping. What "long-term use" looks like is still being worked out.

What about heart benefits?

The SELECT trial showed a 20% reduction in major adverse cardiovascular events in adults with overweight or obesity who already had established cardiovascular disease. That outcome benefit is real and led to an expanded label.

Can you take an oral version instead of injections?

Yes. Rybelsus is a daily tablet for type 2 diabetes; Oral Wegovy is a daily tablet for weight management. Both require empty-stomach administration to absorb properly.

What about compounded semaglutide?

The FDA's stance has tightened as the official supply has caught up. Compounded "semaglutide" is not the FDA-approved product and isn't subject to the same manufacturing oversight. Several state and federal actions in 2025–2026 narrowed the pathways significantly.

Who shouldn't take it?

People with a personal or family history of medullary thyroid carcinoma or MEN2. Caution is needed in people with a history of pancreatitis, severe GI disease, or gallbladder disease. Your prescriber will screen for these.

FDA and regulatory status

Status as of May 5, 2026: FDA-approved across five formulations: Ozempic (December 2017, T2D, weekly injection); Rybelsus (September 2019, T2D, daily oral); Wegovy (June 2021, chronic weight management, weekly injection); Wegovy HD (2025, weight management, weekly injection at 7.2 mg); Oral Wegovy (late 2025/early 2026, weight management, daily oral 25 mg). Approved internationally in the EU, UK, Canada, Australia, Japan, and elsewhere. Status updates land here when they happen.

Notable commentary

A few of the public conversations that pulled semaglutide into the mainstream. Personal accounts and editorial coverage, not clinical evidence on their own.

"I'm just mad it wasn't around ten years ago."

Oprah Winfrey, speaking publicly about her use of a GLP-1 medication for weight management, ahead of her ABC special An Oprah Special: Shame, Blame and the Weight Loss Revolution (March 2024). Coverage in TIME, CNN, and Today.com.

Personal anecdote, not clinical evidence. For educational purposes only.

SELECT cardiovascular trial coverage

The SELECT trial was the first large randomized study to show that a weight-loss medication reduced major cardiovascular events. It changed how the field thought about GLP-1s.

Editorial coverage of clinical-trial results. For educational purposes only.

Want to go deeper? Mechanism, dosing schedules across all formulations, half-life, full STEP/SUSTAIN/SELECT trial detail, side effects, and references. Click to expand.

Background and development

Semaglutide is a 31-amino-acid synthetic peptide developed by Novo Nordisk, with 94% structural homology to native human GLP-1. It is one of the most extensively studied incretin-based therapies, available as injectable and oral formulations across multiple approved indications (type 2 diabetes, chronic weight management) and dose ranges.

Mechanism of action

Semaglutide is a selective GLP-1 receptor agonist. The drug:

  • Stimulates glucose-dependent insulin secretion from pancreatic beta cells
  • Suppresses glucagon secretion (lowering hepatic glucose output)
  • Slows gastric emptying, prolonging satiety after meals
  • Acts in the central nervous system to reduce appetite and food intake

Plasma half-life is approximately 7 days, supporting once-weekly subcutaneous administration. Steady-state is reached after 4 to 5 weeks of consistent dosing.

FDA-approved formulations and dosing

This is a prescription medication. Dosing is established by your prescriber based on indication, response, and tolerability.

Ozempic, weekly injection for T2D

0.25 mg weekly for 4 weeks (titration), then 0.5 mg weekly. May escalate to 1 mg or 2 mg at 4-week intervals based on glycemic response.

Wegovy, weekly injection for weight management

0.25 mg weekly for 4 weeks, escalating in 0.25–0.5 mg steps every 4 weeks to a 2.4 mg maintenance dose. Wegovy HD adds escalation to a 7.2 mg dose.

Rybelsus, daily oral tablet for T2D

3 mg daily for 30 days, then 7 mg, with optional escalation to 14 mg. Must be taken on an empty stomach with no more than 4 oz water, at least 30 minutes before any food, beverage, or other oral medication.

Oral Wegovy, daily oral tablet for weight management

Maintenance 25 mg daily after dose escalation. Same empty-stomach administration requirements as Rybelsus.

The SUSTAIN, STEP, and SELECT programs

SUSTAIN, type 2 diabetes

10 randomized controlled trials evaluating semaglutide in T2D across diverse patient populations. Across the program, semaglutide produced consistent A1C reductions and cardiovascular outcome benefits in defined subgroups.

STEP, chronic weight management

The Phase 3 program for the weight-management indication. Selected results:

  • STEP-1: ~14.9% mean weight loss at 2.4 mg weekly over 68 weeks in adults with overweight or obesity but without T2D.
  • STEP-2: ~9.6% mean weight loss in adults with both T2D and obesity.
  • STEP-3: ~16.0% with intensive behavioral therapy in addition to semaglutide.
  • STEP-1 extension: participants who stopped regained ~two-thirds of weight loss over the year following discontinuation.
  • STEP UP: ~20.7% mean weight loss at 7.2 mg dose, supporting the Wegovy HD approval.

SELECT, cardiovascular outcomes

17,604 adults with overweight or obesity and pre-existing cardiovascular disease, no diabetes. Semaglutide 2.4 mg weekly reduced major adverse cardiovascular events (cardiovascular death, nonfatal MI, nonfatal stroke) by 20% compared with placebo, over a mean follow-up of 39.8 months.

OASIS, oral semaglutide for weight management

Phase 3 trials supporting the oral Wegovy approval. OASIS-4 reported ~16.6% mean weight loss at 25 mg daily over 64 weeks.

Side effects and safety profile

The most common adverse events are gastrointestinal: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite. Most are mild-to-moderate, dose-dependent, and improve with continued dosing.

Approximately 4–6% of trial participants discontinued semaglutide due to adverse events.

Boxed warning: thyroid C-cell tumors observed in rodent studies. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2.

Additional warnings: pancreatitis, severe GI disease, gallbladder disease, hypoglycemia (especially with insulin or sulfonylureas), acute kidney injury, hypersensitivity, retinopathy progression in T2D, and post-marketing reports related to suicidal thoughts under FDA review.

References

  1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). "Once-weekly semaglutide in adults with overweight or obesity (STEP-1)." N Engl J Med, 384(11), 989–1002. PubMed
  2. Garvey WT, Frias JP, Jastreboff AM, et al. (2025). "Semaglutide 7.2 mg in adults with overweight or obesity (STEP UP)." The Lancet. PubMed
  3. Sorli C, Harashima SI, Tsoukas GM, et al. (2017–2019). "SUSTAIN-1 through SUSTAIN-10 trials." Various journals. PubMed
  4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). "Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT)." N Engl J Med, 389(24), 2221–2232. PubMed
  5. Knop FK, Aroda VR, do Vale RD, et al. (2023). "Oral semaglutide 25 mg taken once daily in adults with overweight or obesity (OASIS-4)." The Lancet. PubMed
  6. Wilding JPH, Batterham RL, Davies M, et al. (2022). "Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP-1 trial extension." Diabetes Obes Metab, 24(8), 1553–1564. PubMed
  7. U.S. Food and Drug Administration. "Ozempic Prescribing Information." FDA.gov
  8. U.S. Food and Drug Administration. "Wegovy Prescribing Information." FDA.gov
For educational and research purposes only. This is not medical advice. Semaglutide is a prescription medication; this page does not provide dosing recommendations or substitute for evaluation by a licensed healthcare provider. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does. Information current as of May 2026.